Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024

Spyre Therapeutics, Inc.

Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.
Cash, equivalents, marketable securities, and restricted cash total $485M as of March 31, 2024.
Raised $180M in March 2024 private placement; expected runway into 2027 through clinical readouts.
SPY001 (anti-α4β7) cleared 28-day GLP tox; FIH study to start Q2 2024 with interim data expected year-end 2024.
SPY002 (anti-TL1A) on track for FIH in H2 2024; SPY003 (anti-IL-23 p19) candidate nomination set for mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Spyre Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the first quarter ended March 31, 2024

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001636282-24-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.